论文部分内容阅读
背景:炎症性肠病(IBD)的发病与一系列免疫异常有关。免疫反应受特定的免疫调节细胞调控,包括CD4+CD25+T细胞,而CD4+CD25+T细胞的发育和功能可能受FOXP3基因调控。目的:研究FOXP3的表达特点以及IBD时FOXP3表达的改变。方法:以免疫磁珠分离CD4+、CD4+CD25+和CD4+CD25-T细胞。以逆转录聚合酶链反应(RT-PCR)和蛋白质印迹法检测IBD患者和非IBD对照外周血单个核细胞(PBMC)、肠固有层单个核细胞(LPMC)和肠黏膜组织中FOXP3的表达。结果:CD4+CD25+T细胞中FOXP3mRNA的表达明显强于CD4+T细胞和未分离的PBMC或LPMC。T细胞受体(TCR)激活后,或经白细胞介素(IL)-2、IL-15作用后,PBMC或LPMCFOXP3mRNA或蛋白表达明显增强。12例IBD中9例(75.0%)肠黏膜LPMC中检测到FOXP3mRNA表达,高于对照肠黏膜的47.1%(8/17,P>0.05)。未受刺激的IBD和对照肠黏膜组织中未检测到FOXP3mRNA表达。结论:人类FOXP3的表达受T细胞活化影响。IBD患者肠黏膜LPMC中FOXP3mRNA的表达率有增高的趋势,但与对照肠黏膜相比无显著差异。
Background: The onset of inflammatory bowel disease (IBD) is associated with a series of immune abnormalities. Immune responses are regulated by specific immunomodulatory cells, including CD4 + CD25 + T cells, and the development and function of CD4 + CD25 + T cells may be regulated by the FOXP3 gene. Objective: To investigate the expression of FOXP3 and the change of FOXP3 expression in IBD. Methods: CD4 +, CD4 + CD25 + and CD4 + CD25-T cells were isolated by magnetic beads. The expression of FOXP3 in IBD patients and non-IBD control peripheral blood mononuclear cells (PBMC), intestinal lamina propria mononuclear cells (LPMC) and intestinal mucosa were detected by reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting. Results: The FOXP3 mRNA expression in CD4 + CD25 + T cells was significantly higher than that in CD4 + T cells and non-isolated PBMCs or LPMCs. After activation of T cell receptor (TCR), or through interleukin (IL) -2, IL-15, PBMC or LPMC FOXFO3 mRNA or protein expression was significantly enhanced. FOXP3mRNA expression was detected in LPMC of intestinal mucosa in 9 cases (75.0%) of 12 IBD cases, which was higher than that in control intestinal mucosa (47.1%, 8/17, P> 0.05). FOXP3 mRNA expression was not detected in unstimulated IBD and control intestinal mucosa. Conclusion: The expression of human FOXP3 is affected by T cell activation. The expression of FOXP3 mRNA in intestinal mucosa of IBD patients tended to increase, but there was no significant difference compared with the control intestinal mucosa.